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Abstract 
Poor compliance with conventional asthma medications remains a major problem in 
achieving asthma control. Nigella sativa oil (NSO) is used traditionally for many 
inflammatory conditions such as asthma. We aimed to investigate the benefits of NSO 
supplementation on clinical and inflammatory parameters of asthma. NSO capsules 
500mg twice daily for 4 weeks was used as a supplementary treatment in a randomised, 
double-blind, placebo-controlled trial (RDBPCT) in asthmatics (clinicaltrials.gov: 
NCT02407262). The primary outcome was Asthma Control Test (ACT) score. The 
secondary outcomes were pulmonary function test, blood eosinophils, and total serum 
IgE. Between Jun 1 and Dec 30, 2015, 80 asthmatics were enrolled, with 40 patients in 
each treatment and placebo groups. After 4 weeks, 10 patients had withdrawn from each 
group. Compared to placebo, NSO group showed a significant improvement in mean 
ACT score 21.1 (SD=2.6) vs 19.6 (SD=3.7) (p=0.044) and a significant reduction in blood 
eosinophils by -50 (-155 – -1) vs 15 (-60 – 87) cells/ uL (p=0.013). NSO improved forced 
expiratory volume in 1 second  as percentage of predicted value by 4 (-1.25 – 8.75) vs 1 
(-2 – 5) but non-significant (p=0.170). This RDBPCT demonstrated that NSO 
supplementation improves asthma control with a trend in pulmonary function 
improvement. This was associated with a remakable normalisation of blood eosinophlia. 
Future studies should follow asthmatics for longer periods in a multicentre trial. 
Keywords: Asthma, allergy, eosinophils, black seed, nigella sativa, clinical trial  
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Abbreviations  
ACT: Asthma Control Test 
BMI: Body Mass Index 
CAM: Complementary and alternative treatments 
COX-2: Cyclooxygenase 2 
FEV1: Forced expiratory volume in 1 second 
PEF: Peak expiratory flow 
FEF 25-75%: Forced expiratory flow between 25-75% 
FVC: Forced vital capacity 
GAPP: The Global Asthma Physician and Patient 
GMP: Good manufacturing practice 
IgE: Immunoglobulin E 
IQR: Interquartile range 
ITT: Intention-to-treat 
KAUH: King Abdulaziz University Hospital 
LTB4: Leukotriene B4 
LTC4: Leukotriene C4  
NSO: Nigella sativa L. oil 
NS: Nigella sativa L. 
PGD2: Prostaglandin D2 
RDBPCT: Randomised double-blind placebo-controlled trial  
Saudi FDA: Saudi Food and Drug Authority 
SCTR: Saudi Clinical Trials Registry 
SD: Standard deviation 
Th2: T helper cells type 2 
TQ: Thymoquinone  
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Introduction 
Asthma control is considered to be suboptimal regardless of the availability of 
conventional treatments (Demoly et al., 2012; Price, Fletcher & van der Molen, 2014). 
Data from the Recognise Asthma and Link to Symptoms and Experience (REALISE) 
survey in 2014 for 8000 European patients revealed that the level of asthma control 
remains low (Price, Fletcher & van der Molen, 2014).  
A key concern is poor adherence to asthma medications (Horne et al., 2007; Haughney 
et al., 2008). Common medication-related reasons for non-adherence include 
difficulties with inhaler techniques, the complex course of therapy, adverse events, and 
cost of medications (Bateman et al., 2008; Dima et al., 2015).  
The Global Asthma Physician and Patient (GAPP) Survey reported that 39% of asthma 
patients exchanged or stopped their asthma medication due to adverse events (GAPP, 
2005). 76% of patients and 81% of physicians consider that new treatment options are 
required (GAPP, 2005). The introduction of novel treatment strategies (such as “add-on” 
treatments) is a key step for better asthma control (Lommatzsch & Stoll, 2016). 
Up to 79% of adult patients with asthma used different complementary and alternative 
treatments including herbal medicines, but the evidence for such treatments’  
effectiveness in asthma is very limited (Slader et al., 2006).  A review of plant-based 
medicines used in asthma management found that the evidence is still  unconvincing 
and there is a need for a proper scientific research to support the use of plant-based 
medicines in asthma (Clarke, Lundy & McGarvey, 2015).  Therefore, phytotherapy 
remains a commonly used but poorly investigated element of asthma treatment. 
Traditionally, Nigella sativa L. (NS; Ranunculaceae), known as black seed, is used as a 
food supplement or herbal medicine for a range of inflammatory diseases such as asthma 
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(Lebling & Pepperdine, 2006). A survey of two hundred patients with asthma in Saudi 
Arabia found that 34.5% used unconventional therapies and NS was of the most common 
treatments recorded (Al Moamary, 2008).  
In several preclinical and preliminary clinical studies, NS and its main active 
compound thymoquinone showed positive effects on clinical and biochemical markers of 
asthma inflammation. In mouse models of asthma, Nigella sativa oil (NSO) reduced 
airway hyperresponsiveness, total leukocytes, macrophages, eosinophils, and serum 
levels of total IgE (Balaha et al., 2012). NSO reduced peripheral blood eosinophil count 
in conalbumin sensitised mice (Abbas et al., 2005). NSO prevented inflammatory cell 
infiltration and pathological lesions in the lungs in ovalbumin sensitized rat (Shahzad et 
al., 2009). TQ was able to reduce eosinophilia in ovalbumin sensitised mice (El Gazzar 
et al., 2006a). In a randomised double-blind placebo-controlled trials, NS aqueous extract 
improved asthma symptoms and pulmonary function tests in 29 asthmatics (Boskabady 
et al., 2007). In a randomised double-blind controlled trial, NS aqueous extract improved 
pulmonary function tests of 15 asthmatics (Boskabady, Mohsenpoor & Takaloo, 2010). 
In non-randomised open-label trial, NS combined with bee honey improved lung forced 
vital capacity in 5 asthmatics. In a randomised single-blind controlled trial, NS powder 
enhanced asthma control in combination with immunotherapy in 31 Children  asthmatics 
(Kardani et al., 2013). However, these clinical trials had some limitations. First, sample 
size was limited to a maximum of 29 asthmatics. Second, the investigated outcomes were 
limited in the measurement of only symptoms and pulmonary function except in one trial 
blood eosinophils and total serum IgE were investigated. However, they did not compare 
the results of these biomarkers with placebo. Third, limited information on the chemical 
composition and quality of the investigational NS preparation used in most trials. 
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Therefore, we aimed at conducting a clinical trial with a higher standard of trial design 
(RDBPCT) and sample size (more than 29 adult asthmatics), with inclusion of additional 
asthma biomarkers, and using chemically characterised preparation of NS. 
 
Material and Methods 
Trial design 
The trial was prospective phase II randomised (1:1) double-blind placebo-controlled 
parallel-group clinical trial (RDBPCT). 
Participants 
The inclusion criteria for patients were: adult male/female (age 18-65 years), asthma 
diagnosis based on the Global Initiative for Asthma (GINA) guidelines (Global Intiative 
for Asthma, 2014), asthma symptoms not fully controlled based on ACT score from 5 to 
24, no severe asthma exacerbation in the last four weeks, and able to obtain consent.  
The exclusion criteria were: Serious co-morbid conditions, smoking history, pregnant 
women, taking any preparation containing NSO, known history of hypersensitivity to 
NSO, and taking medications that may interact with NSO such as: 
anticoagulant/antiplatelet, CNS depressants, and immunosuppressants.  
Study settings 
The trial was conducted at medical clinics of respiratory, allergy and family medicine at 
King Abdulaziz University Hospital, Jeddah, Saudi Arabia. 
Ethical approval for the phase II RDBPCT was granted by both the ethical committees of 
University College London (ID: 6419/002) and King Abdulaziz University (ID: 95-15). 
Approval by the national regulatory framework of clinical trials in Saudi Arabia (Saudi 
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FDA) was obtained. The trial was registered with the clinicaltrials.gov database, identifier 
NCT02407262 and The Saudi Clinical Trials Registry (SCTR), identifier 15051902.  
Interventions 
In the treatment group, softgel capsules of cold pressed NSO (0.7% Thymoquinone, 
analysed by High Performance Liquid Chromatography (HPLC) at our labs at the UCL 
School of Pharmacy, London, UK) were used. The treatment product is produced 
according to pharmaceutical GMP standards by Marnys® (Cartagena, Spain; brand name: 
CUMINMAR; batch number: L885) and licensed as an herbal medicinal product in Saudi 
Arabia. The placebo group received similar capsules of virgin olive oil (produced in 
identical appearance by Marnys®, batch number: M398). Both groups received a dose of 
one capsules (500mg oil) twice daily for four weeks.  
Outcomes 
The primary outcome was the ACT score. The Global Initiative for Asthma guidelines 
recommends using one of the numerical asthma control tools such as ACT for scoring the 
level of asthma control and patients’ progress (Global Intiative for Asthma, 2014). ACT 
is one of the best validated instrument to measure asthma control (Cloutier et al., 2012). 
ACT consists of a five questions in total scale of 5-25 with each question (Q1-Q5) scaled 
from 1 to 5. Full control is determined as total ACT score of 25 (Nathan et al., 2004). 
Questions of ACT are the following: 
1. Q1=In the past 4 weeks, how much of the time did your asthma keep you from 
getting as much done at work, school or at home? 
2. Q2=During the past 4 weeks, how often have you had shortness of breath? 
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3. Q3=During the past 4 weeks, how often did your asthma symptoms (wheezing, 
coughing, shortness of breath, chest tightness or pain) wake you up at night or 
earlier than usual in the morning? 
4. Q4=During the past 4 weeks, how often have you used your rescue inhaler or 
nebulizer medication? 
5. Q5=How would you rate your asthma control during the past 4 weeks?  
The secondary outcomes were pulmonary function test, absolute peripheral blood 
eosinophils count, and total serum IgE. 
Pulmonary function test was carried using an Easy on-PC spirometer (ndd Medical 
Technologies, Switzerland). 
 
Randomisation and blinding  
Both the investigator and the patients were blinded to treatment or placebo groups. An 
external medical scientist created a randomisation list with Sealed Envelope Ltd. online 
tool in random permuted blocks of sizes 2 and 4. These mixed block sizes were used to 
reduce the selection bias and achieve a better balance in the allocation of participants. 
The collaborating physicians enrolled participants from their clinics and the investigator 
allocated patients to their concealed study medications. The packaging label of study 
medications contained the randomisation code, study title, expiration date, date of 
packaging, and contact information.  
 
Procedures and compliance check  
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Patients were recruited from the respiratory, allergy, and family medicine clinics at King 
Abdulaziz University Hospital in Jeddah, Saudi Arabia during the period of Jun 1 to Dec 
30, 2015.  
The study duration was four weeks for each patient. During the first visit and after signing 
the study consent form, patients’ baseline demographics, symptoms, co-morbid 
conditions, medications were recorded. The relevant study outcomes were evaluated and 
the ACT was scored by the principal investigator by direct questioning of patients. Then, 
the study medication was dispensed to the patient. After four weeks, the patient returned 
for follow up and was assessed for the completion of outcomes. During the treatment 
period, the principal investigator contacted patients by phone after the first week to check 
compliance and any appearance of side effects.  
 
Blood sampling and biomarkers measurement 
Venous blood samples were collected twice (at the baseline and follow-up visits) for the 
assessment of absolute peripheral blood eosinophils count and total serum IgE. Four 
millilitres fresh blood was used for blood eosinophils counting. Three milliners blood 
was used for total serum IgE testing. The blood analysis was carried out using the 
Celldyn-3500 counter (Abbot) at KAUH’s haematology laboratory. This flow 
cytometry counter provides differential white blood cell counts automatically and used 
to measure blood eosinophil count. Total serum IgE was measured with ImmunoCAP® 
total IgE (Phadia Laboratory Systems, Sweden) at the clinical immunology laboratory 
of KAUH. 
 
Statistical analysis and sample size estimation  
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The study sample size (80) was calculated based on the expected improvement in primary 
outcome (ACT) from an average score of 17 to 20 (effect size = 0.638, power = 80%, the 
level of statistical significance=0.05 and two-sided independent t-test).  
IBM SPSS Statistics 23 software was used for statistical data analysis. The normality of 
data was tested using Shapiro-Wilk test and Q-Q plot. Normally distributed data was 
represented as mean (SD) and independent t-test was used to compare the means of the 
outcomes between two groups. However, non-normal data was represented as median 
(IQR) and Mann–Whitney U testt was used. Intention-to-treat analysis was used for the 
primary outcome. Multiple regression-substitution was used for imputing primary 
outcome missing data, taking into account baseline values. 
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Results  
Subjects 
140 patients with asthma were assessed for eligibility. Of them, 80 patients were 
randomised into treatment and placebo groups. In each group ten patients did not 
complete the study. Reasons for drop-out were variable mainly non-medical such as loss 
of interest and inability to attend. Only four patients had medical reasons such as adverse 
events and asthma exacerbation. The recruitment flow chart and details of drop-out 
reasons are provided in figure 1. The baseline demographics of the recruited patients are 
presented in table 1. Patients were on routine asthma medications that were adjusted and 
optimised according to GINA guidelines for standard asthma management (Global 
Intiative for Asthma, 2014). These included: inhaled short-acting beta agonist 
(salbutamol), inhaled long acting beta agonist (salmetrol or formetrol), inhaled 
corticosteroids (budesonide or fluticasone), oral anti-leukotrienes (montelukast). 
Asthma Control Test 
At baseline, the average levels of symptoms control, represented by the total ACT score, 
were similar between the treatment and placebo group. At the end of the study, the 
average total ACT score was significantly higher in the treatment group over the placebo 
group as shown in table 2. In addition to the total ACT score, the five individual 
parameters of ACT were also analysed. Significant improvement was found in the Q1 
and Q2 of ACT. However, there was a positive improvement in the Q2, Q3 and Q4 of 
ACT but not statistically significant table 2. 
Pulmonary function test  
At the end of the study, there was a trend for improvement in the percentage of predicted 
FEV1 (Forced expiratory volume in 1 second) and PEF (Peak expiratory flow) but not 
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FEF25-75 (Forced expiratory flow between 25-75%) as shown in table 3. However, 
subgroup analysis of patients with low basal predicted FEV1% (<80%), significant 
improvement was found in the treatment subgroup (n=14) vs placebo subgroup (n=15) 
by 8% (3 – 13%) vs 1% (-2 – 5%) (p=0.018), respectively. 
 
Blood outcomes 
There was a marked significant reduction in the absolute peripheral blood eosinophil 
count in the treatment group compared to the placebo group by -50 (-155 – -1) vs 15 (-60 
– 87) cells/ uL (p=0.013), as shown in figure 2. On the other hand, there was no significant 
change found on the total serum IgE level between both groups as shown in figure 3.  
Safety and tolerability  
Three patients (two from the treatment group and one from the placebo group) reported 
three adverse events including; stomach upset, headache, and insomnia. These adverse 
events were mild and self-limited (did not require any treatment or hospitalisation). The 
study treatment is considered to be generally tolerable as only two patients (one from the 
treatment group and one from the placebo group) discontinued the study due to adverse 
events. 
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Discussion
In this study NSO significantly improved asthma control over placebo and showed a trend 
toward pulmonary function improvement with an acceptable safety and tolerability 
profile among adult asthmatic patients. Therefore, this study helps to build up an 
evidence-base for using such supplements in the management of this disease. Unlike 
some other clinical trials, the chemical composition of the main active compound in NSO 
was determined by HPLC analysis and the product was GMP certified. 
Our findings in asthma symptoms control, measured by ACT, were consistent with 
symptoms improvement in previous clinical studies of NS in asthmatic patients. NSO 
enhanced scores of subjective improvement in clinical symptoms of allergic conditions 
including asthma (Kalus et al., 2003). An aqueous extract of NS significantly improved 
the severity of asthma symptoms (Boskabady et al., 2007). The administration of 
powdered NS among asthmatic children with immunotherapy significantly increased 
ACT scores (Sugiono et al., 2013).  
In this study, there was a trend toward pulmonary function improvement in FEV1 and 
PEF in the treatment group but did not reach statistical significance between the treatment 
and placebo groups as in previous studies. However, we found a significant improvement 
between both groups in pulmonary function only among subgroups of patients with below 
normal predicted FEV1% (<80%) at baseline. In a previous clinical study, an aqueous 
extract of NS significantly improved pulmonary function parameters between the 
treatment and placebo group only after 3 months treatment but all patients in this study 
had abnormal pulmonary function at baseline (Boskabady et al., 2007). Also, an aqueous 
extract of NS caused a significant improvement in short-term pulmonary function 
parameters in 30 min until 150min, but it was not compared to placebo and all patients 
15 
 
(15 asthmatic) had abnormal pulmonary function at baseline (Boskabady, Mohsenpoor & 
Takaloo, 2010).  In non-RCT open-label clinical study, NS seeds combined with bee 
honey improved pulmonary function but this study was not placebo controlled and 
included only 5 asthmatics (Al Ameen et al., 2011).  
Interestingly, this study discovered a remarkable reduction of peripheral blood eosinophil 
count. Eosinophil cell plays a major role in asthma inflammation and blood eosinophil 
count is considered to be a vital biomarker in asthma trials (Szefler et al., 2012). To our 
knowledge, this is the first RDBPCT study showed a significant reduction of blood 
eosinophilia by NSO among asthmatic patients. 
The total IgE level in this study did not show any significant changes. This was consistent 
with findings of Kalus et al. (2003) who reported a non-significant IgE changes among 
NSO group, but this study including only 3 asthmatic patients was not statistically 
significant compared to placebo. However, in another clinical study, there was a 
significant reduction of serum total IgE in the group of NS, but this study was conducted 
in children, was not double-blinded placebo-controlled, and NS was combined with a 
probiotics and immunotherapy (Sugiono et al., 2013). 
Several mechanism of actions were suggested for NS or TQ, which may explain its effects 
in asthma. The aqueous extract of NS showed a competitive antagonistic activity on 
histamine H1 receptors (Boskabady & Sheiravi, 2002). TQ inhibited leukotrienes (LTC4 
and LTB4) synthesis in human blood cells (Mansour & Tornhamre, 2004). TQ reduced 
leukotrienes (LTB4 and LTC4) levels by 5-lipoxygenase enzyme inhibition and 
decreased helper cell type 2 (Th2) cytokines level in a mouse model of allergic asthma 
(El Gazzar et al., 2006b). NSO was effective in decreasing histamine and leukotrienes 
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production and increasing PGE2 release in guinea pig model of allergic asthma (Saleh, 
ElDenshary & Mahran, 2012).  
Limitations of our study include the following. The duration of the intervention is 
relatively short (four weeks only). The choice of outcomes was dependent on its 
applicability and availability at the study site. A relatively high drop-out rate which 
resulted from reasons not related to study design or medication, but rather due to 
unexpected reasons not considered initially including the geographical mobility of some 
of the study participants. In addition, the lack of incentives for participants (due to limited 
funding) along with the socioeconomic status of some the participants played a role in 
patient retention rate. 
Conclusion  
NSO supplementation appeared to be effective in enhancing the control of asthma 
symptoms with a trend in pulmonary function improvement. Remarkably, NSO showed 
a reduction of blood eosinophilia. These findings may provide an evidence for the 
potential benefits of NSO supplementation in the clinical management of asthma. To our 
knowledge, this is the first RDBPCT compared the effect of NSO on blood eosinophils, 
and serum total IgE in a relatively larger group of adult patients with asthma versus 
placebo. Future studies should follow patients for a longer period and use additional 
outcomes to validate the benefits of NSO in asthma. 
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Tables 
Table 1. Baseline characteristics of the subjects. 
Variable Treatment (n=40) Placebo (n=40) 
Age 39 (13) 42 (15) 
Men 15 (38%) 18 (45%) 
Women 25 (62%) 22 (55%) 
BMI 28 (5) 30 (8) 
Predicted FEV1% 74(17) 72(16) 
Total ACT 16.0 (3.9) 16.5 (3.6) 
Blood eosinophil count, cells/uL 350 (187 – 711) 300 (135 – 415) 
Total IgE, IU/mL 164 (112 – 468) 224 (57 – 682) 
Values represented as mean (SD), n (%), or median (IQR). 
 
Table 2. Asthma Control Test (ACT) scores. 
Variable Pre-treatment Post-treatment 
 Treatment Placebo P Treatment Placebo P 
Total ACT 16.0 (3.9) 16.6 (3.6) 0.44 21.1 (2.6) 19.6 (3.7) 0.04* 
Q1 (daily functioning)   3.4 (0.9) 3.3 (1.1) 0.62 4.4 (0.6) 3.8 (0.9) 0.01* 
Q2 (SOB frequency) 3.1 (1.0) 3.4 (1.0) 0.22 4.2 (0.7) 3.9 (0.9) 0.28 
Q3 (night symptoms) 3.3 (1.3) 3.6 (1.2) 0.27 4.4 (0.7) 4.0 (1.1) 0.14 
Q4 (use of rescue 
medications) 
3.8 (1.3) 3.7 (1.3) 0.77 4.5 (0.7) 4.2 (1.2) 0.17 
Q5 (overall asthma 
control) 
2.7 (0.7) 2.7 (0.9) 1.00 4.1 (0.6) 3.5 (0.9) 0.01* 
SOB, shortness of breath; Q1-Q5 are the individual questions of ACT. Values represented as mean 
(SD).   
 
Table 3. Pulmonary function test scores. 
 Change in placebo group 
(n=24) 
Change in treatment group 
(n=25) 
p 
Predicted FEV1% 1 (-2 – 5) % 4 (-1.25 – 8.75) % 0.170 
Predicted PEF% 2 (0 – 14.5) % 6.5 (0.25 – 22.75) % 0.279 
Predicted FEF25-
75% 
3 (-6.5 – 16.5) % 2.5 (-7.75 – 18.75) % 0.992 
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Values represented as median (IQR).  FEV1: Forced expiratory volume in 1 second. PEF: Peak 
expiratory flow. FEF 25-75%: Forced expiratory flow between 25-75%. 
 
